Sept 2015 - World Lung Cancer Conference in Denver, USA As of June 24, 2015, partial response had been reported for seven of 25 study participants with PD-L1-positive malignant pleural mesothelioma, of which four were ongoing. Twelve patients had stable disease. “Single-agent pembrolizumab has significant clinical activity in patients with PD-L1-positive MPM [malignant pleural mesothelioma],” said lead study author Evan Alley, MD, PhD, Chief of the Division of Hematology and Medical Oncology at the Penn Presbyterian Medical Center, the University of Pennsylvania in Philadelphia.“The 28% overall response rate and the 76% disease-control rate are better than historical response rates for second-line therapy,” he noted.Median PFS was 5.8 months (95% CI, 3.4–8.2) and the 6-month PFS rate was an “encouraging” 50.0%, Dr. Alley reported.Immunohistochemistry-determined PD-L1 expression levels did not predict the tumor response to pembrolizumab (P = .284), he noted. - See more at: http://www.oncotherapynetwork.com/lung-cancer-targets/second-line-pembrolizumab-shows-%E2%80%98encouraging%E2%80%99-pfs-advanced-mesothelioma#sthash.6gVeoEgq.dpuf